The #EMPOWERCAD study tackles women’s underrepresentation in PCI trials.

An IVL-first approach in women with calcified CAD showed high procedural success, improved 30-day quality of life, and strong safety.

Advancing women in cardiology advances care.

www.jscai.org/articl...

#CardioSky

Benefits of Early SAVR for Asymptomatic Aortic Stenosis Persist a Decade On The final results of RECOVERY add support to addressing severe aortic stenosis right away rather than waiting for symptoms.

🫀 New long-term data highlight benefits of early intervention in asymptomatic severe aortic stenosis. At 10+ years, early #SAVR was linked to lower CV and all-cause mortality vs. watchful waiting ➡️ www.tctmd.com/news/benefits-early-savr...

#CardioSky

Our 10th Anniversary - and we keep getting better every year. Join us in Denver, CO August 6-8, 2026 for interactive case-based learning with world-renowned operators. Check out the agenda at cvinnovations.org/cvi2026/ #cme #conference #cardiology #medsky #cardiosky

Last weekend at #ACC26 was 😍

✨Celebrating & growing our community
✨Packed panel with Pfizer
✨Dr Roxana Mehran becoming @accintouch.bsky.social President
✨2025 Mentorship Award winner Dr. Preet Shaikh presenting research developed through the Awards

We're moving cardiology forward
#CardioSky

Left atrial appendage closure fails to match medical therapy in high-risk AF Left atrial appendage closure fails to match medical therapy for preventing stroke and major events in high-risk atrial fibrillation, the CLOSURE-AF trial shows.

From #ACC2026 - Left atrial appendage closure fails to match medical therapy for preventing #stroke and major events in high-risk atrial fibrillation, the CLOSURE-AF trial shows.

👉 buff.ly/wXa91qR

#CardioSky #MedNews

Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial There was no significant difference in all-cause mortality at 10 years between PCI and CABG for patients with unprotected left main coronary artery disease and no additional complex lesions, indicatin...

“Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.”
Publié ce jour dans @thelancet.com.
#MedSky #CardioSky
www.thelancet.com/journals/lan...

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications Injectable GLP-1 medicines have been shown to improve cardiovascular and renal outcomes in patients with type 2 diabetes, but do the oral agents demonstrate the same benefits?

Injectable #GLP1 medicines have been shown to improve cardiovascular and renal outcomes in patients with #Type2Diabetes, but do the oral agents demonstrate the same benefits?

👉 buff.ly/Rj4TWst

#CardioSky

A picture of Irish countryside with event banners overlaid

🚨BOOK NOW

💚 Irish regional webinar: Case-based discussions
📅 Tuesday 19 May 2026
🖥️ Webinar
📜 2 BSE points

Programme coming soon - secure your place: bsecho.org/iCore/Events/Event_displ...

#echosky #cardiosky

New multicenter study following nearly 2,000 patients for 10 years after TAVR with self-expanding valves reinforces why sex-specific analysis is essential and highlights a critical nuance: women experienced more stroke and transient ischemic attacks.

Women make up ~50% of real-world TAVR patients but remain underrepresented in trials. A 10-year study (~2,000 pts, 54.9% women) shows better survival in women, similar valve durability, but higher stroke risk.

Sex-specific care matters.

Read more: link.springer.com/ar...

#CardioSky

🩻 One way to protect yourself in the #CathLab from radiation is by correctly wearing your gear. Share a picture of yourself wearing your lead and SCAI hat and let us know your best radiation safety tips! ☢️

#SCAIHatDay #PhysicianWellbeing #SCAIWellness #CardioSky

Adding evolocumab to statins reduces MACE even without overt atherosclerosis Adding evolocumab to background statin therapy substantially reduces the risk for a major adverse cardiovascular event in high-risk patients with diabetes who do not have significant atherosclerosis.

From #ACC2026 - Adding evolocumab to background statin therapy substantially reduces the risk for MACE in high-risk patients with #diabetes who do not have significant atherosclerosis.

👉 buff.ly/T8IcYzB

#CardioSky #MedNews

Considering applying to the level 3 pilot project? Our President, Dan Augustine, outlines why cardiologist support is so important for those applying

Click here for further details: www.bsecho.org/Public/News/Articles/202...

#echosky #cardiosky

#Cardioobstetrics 📢
🫀April =CPP Congress month!
🤰🏽👀you there!

#Cardiosky #medsky #obgynsky #reprosky #mfmsky

The effect of adding visual summaries to data visualizations on patient judgments of hypertension control AbstractObjectives. To test the impact of visual summaries of blood pressure (BP) data (eg, stoplight and gradient displays), within the context of a patie

"...simplified verbal summaries alone are effective in helping #patients extract important gist information (i.e., “I am above my goal”) from noisy personal health data." academic.oup.com/jamiaopen/ar...

#MedSky #CardioSky #PatientExperience #HealthLiteracy #PublicHealth #HealthCommunication

Almost time! 💥 Sponsorship & satellite opportunities open April 8 at 1:00 PM EDT for #TCT2026 🌴 Spots go fast — be ready!

Sponsorships 👉 https://ow.ly/eRv850YCCpT
Satellites 👉 https://ow.ly/ETb950YCCpS

#CardioSky #MedSky

#cardiosky #echosky #emimcc

Protected PCI and Cardiogenic Shock Interventional Octagon Submissions Open - Cardiovascular Innovations Please join us at the CVI’s Interventional Octagon competitive case-based learning webinar on 4/14/26 at 9 pm ET. This CME session will focus on Protected PCI and Cardiogenic Shock.  Fellows...

Submit cases for the Interventional Octagon by 4/5. Topic: Protected PCI and Cardiogenic Shock. Finalists earn travel grants to CVI in Denver 8/6-8/8. Complimentary webinar 4/14 at 9 pm ET. Submissions/webinar registration at: cvinnovations.org/2026/03/05/c... #MedSky #CardioSky

From LAAC vs. NOACs to hybrid AI adjudication, DCRI faculty shaped the science at #ACC26. Catch up on the sessions you may have missed: dcri.org/acc26 #CardioSky #HeartDisease

🔍Looking to deepen your expertise in #tricuspid #TEER interventions? The comprehensive #SCAITTEEREbook covers every step of the procedure, from patient selection to complication management.

Download the ebook for free➡️ https://ow.ly/Oh4F50YyRLv

#InterventionalCardiology #CardioSky

Quality Improvement for Institutions

Great funding opportunity from @accintouch.bsky.social to conduct QI activities! cvquality.acc.org/accreditatio... #cardiosky

Dr. Amar Krishnaswamy can’t wait for #NYValves2026 — and neither can we! 🎉

Get ready to walk away with fresh insights for patient care and long-term planning that’ll help you deliver better outcomes. 💪

Secure your spot today! https://ow.ly/Xhiw50YxJSt

#CardioSky #MedSky

Universal Non-invasive Cardiac Imaging: Which Modality Best Combines Anatomy and Physiology? Hybrid cardiac imaging techniques enhance coronary artery disease diagnosis, physiologic assessment, risk stratification, and cost...

New publication in EMJ Radiology, options for noninvasive hybrid cardiac imaging www.emjreviews.com/en-us/amj/ra... #cardiosky

📢 Der neue DGK-Jahresbericht 2025 ist da! 🆕
Tauchen Sie auf Herzmedizin.de direkt in die spannendsten Themen ein.
➡️ herzmedizin.de/meta/ueber-u...
#DGK #Kardiologie #CardioSky

Discontinuation of Beta-Blocker Therapy after Myocardial Infarction | NEJM The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary coronary-ar...

“Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.”
Publié ce jour dans le @nejm.org.
#MedSky #CardioSky
www.nejm.org/doi/full/10....

GLP-1 Receptor Agonists.

www.nejm.org/doi/full/10....

@nejm.org
#CardioSky #MedSky #Cardiology #EndoSky #GLP1RA

#SCAIHatDay advocates for workplace safety standards and fosters a collaborative community to achieve positive change like the #SCAI2025 summit resulting in the new ALARA+ initiative to reduce radiation exposure and improve safety in the #CathLab.

Learn more ➡️ https://ow.ly/J3yZ50YySeV

#CardioSky

Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation | NEJM Catheter-based closure of the left atrial appendage is an alternative to oral anticoagulation for stroke prevention in patients with atrial fibrillation. The effectiveness of this strategy, as comp...

"Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation."
Publié ce jour dans le @nejm.org.
#MedSky #CardioSky
www.nejm.org/doi/full/10....

New application deadline: April 10. 2026 Mentorship Awards.

The 2026 Mentorship Awards application window has been extended! 🎉

Mentors and mentees now have until April 10 to apply for this unique opportunity to collaborate, share expertise, and advance in cardiology.

Apply here: womenasonepulse.org/...

#WomenAsOneAwards #CardioSky

Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management Despite the substantial burden of heart failure in kidney transplant recipients, the exclusion of this population from clinical trials raises concerns about the safety and efficacy of GDMT in these…

Despite the substantial burden of HF in kidney transplant recipients, the exclusion of this population from clinical trials raises concerns about the safety and efficacy of GDMT in these patients.

What are the concerns and how can they be overcome?

👉https://buff.ly/172WzvE

#CardioSky

A graphic saying 'Echo job of the week'

JOB OF THE WEEK

Looking for a change? Betsi Cadwaladr University Health Board are recruiting a Highly Specialised Cardiac Physiologist Echocardiography - closing Wednesday 6 April 2026: www.jobs.nhs.uk/candidate/jobadvert/H905...

#echosky #cardiosky